Pharmaceutical composition for vaginal administration of medicinal tools (options), the method of prevention or treatment of dysmenorrhea, the method of prevention or treatment of preterm labor

 

Proposed composition comprising the agonist-adrenergic receptors in bioclean media. The composition preferably includes terbutaline in polycarbophil. In addition, a local application of agonist-adrenergic receptors for the treatment or prevention of dysmenorrhea or premature birth. The invention provides the local concentrations of the drug sufficient to provide therapeutic action without many negative side effects. 5 C. and 13 C.p. f-crystals, 5 tab., 7 Il.

Description text in facsimile form (see graphic part).

Claims

1. Pharmaceutical composition for vaginal administration of medicinal products for the prevention or treatment of dysmenorrhea or premature delivery, comprising a therapeutically effective amount of agonist-adrenergic receptor and a pharmaceutically acceptable biocracy media, in which biocracy media is a cross-linked polymer polycarboxylic acid.

2. Composition under item 1, in which the agonist-adrenergic receptors weight.

4. Composition under item 1, in which the crosslinked polymer of the carboxylic acid is polycarbophil.

5. Composition under item 1, in which agonist-adrenergic receptors is terbutaline in an amount of about 1 to 4 mg per dose of the composition from about 1 to 1.5,

6. The method of prevention or treatment of dysmenorrhea, including vaginal introduction of the pharmaceutical composition under item 1.

7. The method according to p. 6, in which the agonist-adrenergic receptors is terbutalina, and the dose of injected composition contains from 1 to 4 mg of terbutalina.

8. The method according to p. 6, in which the composition is administered every 12-48 hours during dysmenorrhea.

9. The method according to p. 6, in which the composition is administered every 24 h during dysmenorrhea.

10. The method of prevention or treatment of preterm labor, including vaginal introduction of the composition under item 1 in a therapeutically effective amount.

11. The method according to p. 10, whereby the agonist-adrenergic receptors is terbutalina, and the dose of injected composition contains from 1 to 4 mg of terbutalina.

12. The method according to p. 10, in which the composition is administered every 12-48 hours

13. The method according to p. 10, in which the composition is administered every 24 hours

14. the cartonnage funds in the blood to harmful values, comprising a therapeutically effective amount of the medicinal product, together with crosslinked polymer polycarboxylic acid as bolakovo pharmaceutical carrier.

15. The composition according to p. 14, in which the drug is different than progesterone or remedy against sexually transmitted diseases.

16. The composition according to p. 14 or 15, in which the crosslinked polymer of the carboxylic acid is polycarbophil.

17. Pharmaceutical composition for vaginal administration of medicinal means during menstruation, containing cross-linked polymer polycarboxylic acid as bolakovo pharmaceutical carrier and a therapeutically effective amount of the drug.

18. The composition according to p. 17, in which the crosslinked polymer of the carboxylic acid is polycarbophil.

 

Same patents:

The invention relates to new derivatives of benzothiadiazole, benzoxazoles and benzodiazines formula I in free base form or in the form of a pharmaceutically acceptable acid salt additive that can be used as an anxiolytic drug in the treatment of any condition, which is associated with increased endogenous levels of CRF or in which violated the regulation of the hPa system (hypothalamic - pituitary), or various diseases that are caused by CRF1or the manifestation of which contributes CRF1such as arthritis, asthma, allergies, anxiety, depression, etc

-acetoxy-3-phenylpropionate-6-methylpregna-4,6-dien - 20-he, with gestagennami activity, and the drug based on it" target="_blank">

The invention relates to medicine, more specifically to medicines designed to maintain pregnancy, and may find application in obstetrics and gynecology
The invention relates to medicine, namely to obstetrics, and can be used for doing the first half of pregnancy induced

The invention relates to a heptapeptide analogs of oxytocin General formula S-Z, where S is Hexapeptide group, a Z represents-NR-CH(Q)-CH2HE, Q represents (CH2)-NH-A, n is a number from 1 to 6, a represents N, and R represents a CH3or2H5with the activity of antagonists of oxytocin

The invention relates to medicine, namely to obstetrics and Perinatology

The invention relates to medicine

The invention relates to new derivatives of benzothiadiazole, benzoxazoles and benzodiazines formula I in free base form or in the form of a pharmaceutically acceptable acid salt additive that can be used as an anxiolytic drug in the treatment of any condition, which is associated with increased endogenous levels of CRF or in which violated the regulation of the hPa system (hypothalamic - pituitary), or various diseases that are caused by CRF1or the manifestation of which contributes CRF1such as arthritis, asthma, allergies, anxiety, depression, etc

The invention relates to new derivatives of benzothiadiazole, benzoxazoles and benzodiazines formula I in free base form or in the form of a pharmaceutically acceptable acid salt additive that can be used as an anxiolytic drug in the treatment of any condition, which is associated with increased endogenous levels of CRF or in which violated the regulation of the hPa system (hypothalamic - pituitary), or various diseases that are caused by CRF1or the manifestation of which contributes CRF1such as arthritis, asthma, allergies, anxiety, depression, etc

The invention relates to medicine, in particular to Oncology, obstetrics and gynecology

The invention relates to the field of medicine and relates to self-adhesive drug composition for percutaneous use of estrogen combined with progestogen containing 25-90 wt.% self-adhesive acrylate copolymer, 1-15 wt
The invention relates to medicine, in particular to the gynecologist, and can be used for the treatment of obesity

The invention relates to veterinary

The invention relates to new thienopyrimidine formula I, their pharmaceutically acceptable salts, having the effect of inhibitors of phosphodiesterase V, which can be used to combat diseases of the cardiovascular system and for the treatment and/or therapy of disorders, to pharmaceutical compositions in a form suitable for the treatment

The invention relates to medicine, namely to gynecology and venereology, and can be used for the treatment of urogenital chlamydia trachomatis in women
The invention relates to medicine
The invention relates to the field of medicine

The invention relates to pharmacy and medicine
The invention relates to the field of pharmaceutical industry and relates to antifungal pharmaceutical composition comprising ketoconazole and as auxiliary substances, antioxidant, organic alcohol, emulsifier, ether of glycerol, ether p-oksibenzoynoy acid, vegetable oil, methylcellulose and/or sodium carboxymethyl cellulose and water, and method of its production by homogenization of the emulsion from the water, ether p-oksibenzoynoy acid, emulsifier, methylcellulose and/or sodium carboxymethyl cellulose and vegetable oil with a solution of ketoconazole in organic alcohol containing an antioxidant and an ester of glycerol
Up!